JP6146934B2 - シスタチオンβ−シンターゼの精製 - Google Patents

シスタチオンβ−シンターゼの精製 Download PDF

Info

Publication number
JP6146934B2
JP6146934B2 JP2015503433A JP2015503433A JP6146934B2 JP 6146934 B2 JP6146934 B2 JP 6146934B2 JP 2015503433 A JP2015503433 A JP 2015503433A JP 2015503433 A JP2015503433 A JP 2015503433A JP 6146934 B2 JP6146934 B2 JP 6146934B2
Authority
JP
Japan
Prior art keywords
cbs
protein
truncated
coli
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015503433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512639A (ja
JP2015512639A5 (cg-RX-API-DMAC10.html
Inventor
リチャード ジー． カリージョ，
リチャード ジー． カリージョ，
ジャン ピー． クラウス，
ジャン ピー． クラウス，
トーマス マイタン，
トーマス マイタン，
デイビッド ナベー，
デイビッド ナベー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
University of Colorado Denver
Original Assignee
University of Colorado Colorado Springs
University of Colorado Denver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs, University of Colorado Denver filed Critical University of Colorado Colorado Springs
Publication of JP2015512639A publication Critical patent/JP2015512639A/ja
Publication of JP2015512639A5 publication Critical patent/JP2015512639A5/ja
Application granted granted Critical
Publication of JP6146934B2 publication Critical patent/JP6146934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015503433A 2012-03-26 2013-03-25 シスタチオンβ−シンターゼの精製 Active JP6146934B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US61/615,629 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
US13/830,494 2013-03-14
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017078808A Division JP6839595B2 (ja) 2012-03-26 2017-04-12 シスタチオンβ−シンターゼの精製

Publications (3)

Publication Number Publication Date
JP2015512639A JP2015512639A (ja) 2015-04-30
JP2015512639A5 JP2015512639A5 (cg-RX-API-DMAC10.html) 2015-10-15
JP6146934B2 true JP6146934B2 (ja) 2017-06-21

Family

ID=49212017

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015503433A Active JP6146934B2 (ja) 2012-03-26 2013-03-25 シスタチオンβ−シンターゼの精製
JP2017078808A Active JP6839595B2 (ja) 2012-03-26 2017-04-12 シスタチオンβ−シンターゼの精製
JP2019187777A Active JP6952361B2 (ja) 2012-03-26 2019-10-11 シスタチオンβ−シンターゼの精製

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017078808A Active JP6839595B2 (ja) 2012-03-26 2017-04-12 シスタチオンβ−シンターゼの精製
JP2019187777A Active JP6952361B2 (ja) 2012-03-26 2019-10-11 シスタチオンβ−シンターゼの精製

Country Status (11)

Country Link
US (4) US9243239B2 (cg-RX-API-DMAC10.html)
EP (3) EP3569706A1 (cg-RX-API-DMAC10.html)
JP (3) JP6146934B2 (cg-RX-API-DMAC10.html)
CN (1) CN104540940B (cg-RX-API-DMAC10.html)
AU (1) AU2013240003B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014023570B1 (cg-RX-API-DMAC10.html)
CA (1) CA2867719C (cg-RX-API-DMAC10.html)
HK (1) HK1246350B (cg-RX-API-DMAC10.html)
IL (2) IL234635B (cg-RX-API-DMAC10.html)
IN (1) IN2014DN07920A (cg-RX-API-DMAC10.html)
WO (1) WO2013148580A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017121255A (ja) * 2012-03-26 2017-07-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト シスタチオンβ−シンターゼの精製
US11077175B2 (en) 2015-11-09 2021-08-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11324811B2 (en) 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
US11400143B2 (en) 2013-01-29 2022-08-02 The Regents Of The University Of Colorado Compositions and methods for treatment of homocystinuria

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US20220315965A1 (en) * 2019-06-25 2022-10-06 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
MX2021015966A (es) * 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
CA2788689C (en) 2010-02-04 2019-07-02 The Board Of Regents Of The University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017121255A (ja) * 2012-03-26 2017-07-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト シスタチオンβ−シンターゼの精製
US10160962B2 (en) 2012-03-26 2018-12-25 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
JP2020000259A (ja) * 2012-03-26 2020-01-09 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト シスタチオンβ−シンターゼの精製
US10941392B2 (en) 2012-03-26 2021-03-09 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US11400143B2 (en) 2013-01-29 2022-08-02 The Regents Of The University Of Colorado Compositions and methods for treatment of homocystinuria
US12661391B2 (en) 2013-01-29 2026-06-23 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11077175B2 (en) 2015-11-09 2021-08-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11771745B2 (en) 2015-11-09 2023-10-03 The Regents Of The University Of Colorado Compositions and methods for treatment of homocystinuria
US12194082B2 (en) 2015-11-09 2025-01-14 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US11324811B2 (en) 2017-04-17 2022-05-10 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
US12042529B2 (en) 2017-04-17 2024-07-23 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria

Also Published As

Publication number Publication date
US10160962B2 (en) 2018-12-25
US20190055537A1 (en) 2019-02-21
EP3263701A1 (en) 2018-01-03
AU2013240003A1 (en) 2014-10-02
US9243239B2 (en) 2016-01-26
EP3569706A1 (en) 2019-11-20
IL234635B (en) 2018-12-31
US10941392B2 (en) 2021-03-09
EP3263701B1 (en) 2019-06-19
AU2013240003B2 (en) 2018-04-19
JP6952361B2 (ja) 2021-10-20
CA2867719A1 (en) 2013-10-03
JP2015512639A (ja) 2015-04-30
WO2013148580A1 (en) 2013-10-03
BR112014023570B1 (pt) 2022-03-15
HK1246350B (en) 2020-05-15
CN104540940A (zh) 2015-04-22
US20160177287A1 (en) 2016-06-23
EP2831229A1 (en) 2015-02-04
EP2831229B8 (en) 2018-10-17
IL263162B (en) 2019-11-28
US20200131497A1 (en) 2020-04-30
IN2014DN07920A (cg-RX-API-DMAC10.html) 2015-05-01
BR112014023570A2 (pt) 2021-06-01
CA2867719C (en) 2020-08-11
EP2831229B1 (en) 2017-10-18
CN104540940B (zh) 2018-03-06
JP2017121255A (ja) 2017-07-13
IL263162A (en) 2018-12-31
US20130251700A1 (en) 2013-09-26
JP6839595B2 (ja) 2021-03-10
JP2020000259A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
JP6952361B2 (ja) シスタチオンβ−シンターゼの精製
HK1246350A1 (en) Purification of cystathionine beta-synthase
Mihara et al. cDNA cloning, purification, and characterization of mouse liver selenocysteine lyase: candidate for selenium delivery protein in selenoprotein synthesis
US10624959B2 (en) Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
JP2022050589A (ja) ホモシスチン尿症の治療する組成物および方法
US20040033219A1 (en) Human cystathionine beta-synthase variants and methods of production thereof
US20170073650A1 (en) Recombinant therapeutic glycine n-acyltransferase
HK40016298A (en) Purification of cystathionine beta-synthase
US20250340852A1 (en) Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine
Tryon The Role of Potassium in Betaine-Homocysteine Methyltransferase

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170515

R150 Certificate of patent or registration of utility model

Ref document number: 6146934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250